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Background: The initial dose of recombinant Follicle Stimulating Hormone [rFSH] to be used in assisted
reproduction treatment depends on several factors, mainly the cause of the infertility and the patient’s age. For
young patients [≤35 years] usually an initial dose of around 150 IU of rFSH is recommended, but there are no
studies proving that this should actually be the standard initial dose. We aimed to report the experience of
a low-cost Human Reproduction Center where a dose of 100 IU of rFSH was used for controlled ovarian
hyperstimulation [COH].
Findings: An observational prospective study was performed on 212 women aged ≤38 years old that underwent
high-complexity assisted reproduction treatments. The patients’ infertility was mainly caused by tuboperitoneal,
idiopathic or male factors. Controlled ovarian stimulation was performed using 100 IU of rFSH. Regarding the COH,
53.8% of the patients presented a satisfactory response, 25.9% low response, 14.2% hyper-response, and 6.1%
developed ovarian hyperstimulation syndrome. Of the 55 patients with poor response, 20 started a new cycle with
an initial dose of 200 IU of rFSH; 65% showed a satisfactory response, 10% a poor response, 20% a hyper-response,
and 5% developed OHSS.
Conclusion: The initial dose of 100 IU of rFSH was considered adequate for controlled ovarian hyperstimulation,
meeting the aim to reduce the costs of the assisted reproduction treatment.
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Conjugal infertility is characterized by the absence of
spontaneous pregnancy after the minimum period of
twelve months, with the practice of regular and unpro-
tected intercourse [1]. Although infertility is not a phys-
ical problem and does not threaten the life of the
individual, marital infertility is related to emotional,
mental and social problems, as the act of procreation is
one of the goals and desires of the human [2]. Studies
conducted by the British Association of Counselling in
Infertility and the Royal College of Obstetricians and
Gynecologists demonstrated that infertility is related
to low productivity and the loss of financial reserves
for that country [3]. Approximately 20% of adults of* Correspondence: bianca.bianco@hotmail.com
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stated.reproductive age face difficulties to conceive. In Brazil,
data of the Ministry of Health considered to be under-
estimated reported the existence of at least 278,000 in-
dividuals affected by infertility [4], however it is
believed that approximately 30,000,000 people in Brazil
are infertile.
Since the birth of the first in vitro fertilization [IVF]
baby almost 30 years ago, dramatic developments have
occurred in assisted reproductive technology. The ap-
proach of maximizing pregnancy rates per cycle has led
to very complex and costly ovarian hyperstimulation
protocols. Ovarian stimulation has been applied with the
aim of increasing the number of oocytes in order to
compensate for inefficiencies of the IVF procedure, en-
abling the selection of one or more embryos for transfer
[5]. In the context of improved laboratory performance,
the need for a large number of oocytes as an integral
part of a successful IVF program may be questioned [6].l Ltd. This is an Open Access article distributed under the terms of the Creative
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lation are complex and expensive, and can be associated
with negative effects such as ovarian hyperstimulation
syndrome [7] and impaired luteal phase [6]. Thus, there
has been increasing interest in identification and the rela-
tive performance of tests of ovarian reserve prior to
embarking on controlled ovarian stimulation [8].
Several parameters have been postulated as predictors
of ovarian response. Because ovarian function cannot be
measured directly, the use of serum markers [FSH (Fol-
licle Stimulation Hormone), inhibin B, 17-β-estradiol
and anti-Müllerian hormone (AMH)] and/or ultrasound
variables [ovarian volume, measurement of antral folli-
cles, ovarian stromal blood flow] have been proven useful
although limited [8]. These markers do not reflect the
complex follicular dynamics and none of them shows
strong correlation with the population of primordial
follicles that remain in the gonad. In other words, these
tests do not reveal the cohort of inactive follicles
responsible for the continuation of ovulatory cycles or
reproductive potential [9].
In the same context, the initial dose of rFSH that
should be used depends on several factors, mainly the
cause of the infertility and the patient’s age. According
to Devroey et al. (1998) [10], the initial dose of FSH
should be around 150 IU or 225UI for young patients
[<35 years] undergoing assisted reproduction treatment
of high complexity, to be adjusted according to the
ultrasound control [antral follicle counting] and/or dos-
age of plasma estradiol, but so far there are no studies
proving that this should actually be the standard initial
dose.
Considering the lack of data concerning the recom-
mended initial dose of rFSH for patients undergoing
assisted reproduction treatment, we report here the ex-
perience of a low-cost Human Reproduction Center




An observational prospective study was performed on
212 women [mean age 31.6 ± 3.4 years old] who under-
went high-complexity assisted reproduction treatments
at Instituto Ideia Fértil - Centro de Reprodução Humana
e Genética da Faculdade de Medicina do ABC, Santo
André/SP, Brazil. The inclusion criteria were: tube peri-
toneal, unexplained or male factor infertility, age ≤38 years
old, serum FSH [≤10.0 mIU/ml], TSH [<4mIU/L] and
prolactin [<25 ng/ml] within normal limits, both ovar-
ies present and without any morphological abnormalities,
normal ovulatory cycles [25 to 35 days], body mass index
[BMI] ≤30, no history of inadequate ovulatory response
[poor responder] and no evidence of endocrine diseasessuch as hyperprolactinemia, thyroid dysfunction or polycys-
tic ovary syndrome. Exclusion criteria were: age >38 years
old, high-complexity ovulation induction protocols
with rFSH starting dose >100 IU, low-complexity
protocols, patients with polycystic ovary syndrome,
moderate/severe endometriosis [grades III and IV],
previous history of ovarian surgery and/or radiation/
chemotherapy.
The investigation into the cause of infertility included
a hormonal and biochemical profile, testing for sexually
transmitted diseases, imaging examinations, investiga-
tion of genetic and/or immunological abnormalities, and
semen analysis of the partner, hysterosalpingography,
hysteroscopy and laparoscopy [performed in all women
up to 36 years of age and also in patients over 36 when-
ever there were symptoms or abnormalities on the im-
aging examinations]. If no abnormalities were found in
these exams, the infertility was classified as unexplained.
Anatomic tubal abnormalities preventing the proper
functioning of the tubes, such as tubal obstruction, func-
tional changes caused by pelvic inflammatory disease,
endometriosis, or previous tubal surgery were consid-
ered tubeperitoneal factors. These abnormalities were di-
agnosed by hysterosalpingography and/or laparoscopy.
According to the criteria of the World Health Organization
[WHO, 2010] [11], when a patient’s partner presented
an initial concentration of less than 15 million sperm/ml,
5 million/mL rapid progressive after sperm pro-
cessing, or asthenospermia [less than 40% of motile
spermatozoa considering rapid progressive or nonpro-
gressive or less than 32% if we consider only the rapid
progressive sperms], the case was classified as male
factor infertility.
Clinical and laboratory data were collected only after
explaining the objectives of the study and obtaining a
signed informed consent form, as approved by the local
Research Ethics Committee.
Ovarian stimulation protocol
To the patients who met the inclusion criteria an initial
daily dose of 100 IU of rFSH was administered for 10
days, starting on the second day of menstruation. As of
the 6th day and until the 10th day, the antagonist was
also administered. Between day 10 and 11, when the fol-
licles reached a diameter of approximately 17 mm, as
determined by transvaginal ultrasound, the patients were
given human chorionic gonadotropin [hCG], and on day
13 oocyte retrieval was performed.
Patients who did not present a good response within
the first eight days, i.e., whose follicles did not show sat-
isfactory growth [at least 14 mm or did not grow at least
4 follicles over 10 mm] for further treatment, had their
treatment cycles canceled. A new cycle can be started
Table 2 Classification of patients with poor response to
the initial dose of 100 IU of rFSH according to their
response to controlled ovarian hyperstimulation with an











Satisfactory 13 65% 0.538 [0.929] 5.46 [1.677]
Poor 2 10% 0 1.5 [1.576]
Hyper 4 20% 1.25 [2.165] 8.5 [2.179]
OHSS 1 5% 3.0 14.0
COH - controlled ovarian hyperstimulation, OHSS – Ovarian
hyperstimulation syndrome.
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indication.
With regard to the controlled ovarian stimulation we
considered: i] Ovarian hyperstimulation syndrome [OHSS],
characterized by multiple ovarian follicles [≥20 follicles]
accompanied by ≥4000 IU of serum estradiol and possible
clinical symptoms such as ascites, hematological changes
[hemoconcentration], pleural effusion, and liver and/or
coagulation abnormalities according to the classification
proposed by Golan et al. [1989] [12]; ii] Hyperresponse,
when after 6 days of ovarian stimulation with gonadotro-
pins there was the development of ≥12 ≤ 19 follicles, with-
out clinical symptoms of OHSS; iii] Poor response, when
after 6 days of ovarian stimulation with gonadotropins
only up to 3 follicles smaller than 14 mm developed; and
iv] Satisfactory response, when after 6 days of ovarian
stimulation with gonadotropins 4 to 12 follicles larger
than 14 mm had developed.
Results
The study included 212 patients who underwent high-
complexity assisted reproduction treatments, of which
53.8% [114/212] presented a satisfactory response to con-
trolled ovarian hyperstimulation, 25.9% [55/212] were
classified as poor responders, 14.2% [30/212] showed a
hyper-response, and 6.1% [13/212] developed ovarian hy-
perstimulation syndrome [OHSS], as shown in Table 1.
Considering the patients with poor response, 20 out of
55 started a new treatment cycle with an initial dose of
200 IU of rFSH, and 65% [13/20] showed a satisfactory
response, 10% [2/20] a poor response, 20% [4/20] a
hyperresponse, and 5% [1/20] developed OHSS, as
shown in Table 2.
Discussion
In vitro fertilization is a complex multistep process that
comprises collection of oocyte-containing follicles after
controlled ovarian hyperstimulation with FSH, oocyte
fertilization, embryo development, embryo transfer to
the uterus, and implantation. All these steps are critical
for successful IVF. However, the initial critical step of
this complex procedure is the COH whose aim it is toTable 1 Classification of patients according to their
response to controlled ovarian hyperstimulation with an











Satisfactory 114 53.8% 0.184 [0.487] 5.561 [1.933]
Poor 55 25.9% 0.036 [0.187] 1.727 [1.119]
Hyper 30 14.2% 0.966 [1.516] 10.5 [2.642]
OHSS 13 6.1% 0.307 [0.605] 16.0 [5.857]
COH - controlled ovarian hyperstimulation, OHSS – Ovarian
hyperstimulation syndrome.safely obtain a high number of mature oocytes, so as
to allow the selection of the most viable embryo for
transfer. Both quantitative and qualitative factors in oo-
cyte production have a high influence on the IVF out-
come. The significant inter-individual variability regarding
COH with rFSH is one of the most challenging issues in
IVF treatment. The goal is to transfer a single embryo and
thus reduce the risk of multiple pregnancies, the main
complication of IVF [13,14].
Since both practitioners and patients believed that the
replacement of several embryos increased the success
rate, multiple embryo replacement was the rule. Very
slowly one realized that this practice had considerable
side effects. The price to be paid for the multiple births
is enormous, both in financial and health terms, but also
in terms of psychological suffering [15,16]. An important
move away from this model occurred only a few years
ago with the introduction of single embryo transfer
[17,18].
The process that started with single embryo transfer
should eventually result in a global ’patient-friendly’
approach. Patient-friendly assisted reproductive treat-
ment includes four different aspects or criteria: cost-
effectiveness, equity of access, risk minimization and
burden minimization for the patients [19].
In 1996, Edwards et al. were the first to express con-
cern with regard to contemporary ovarian stimulation
approaches for IVF and called for the use of a milder
stimulation protocol [20]. The aim of mild stimulation is
to develop safer and more patient-friendly protocols in
which the risks of treatment are minimized [7,19,21-23].
The term “low-cost IVF” was coined by Professor Alan
Trounson at a World Health Organization meeting in
Geneva in 2001. The concern of the World Health
Organization had always been to promote advances
in health care in low resource economies. A milder
stimulation protocol offers the same advantages as
natural-cycle IVF, but has higher efficacy by recruiting few
dominant follicle in addition to a many codominant folli-
cles that do not develop spontaneously in a natural cycle
[7,24]. However, there are reservations about the efficacy
Barbosa et al. Journal of Ovarian Research 2014, 7:11 Page 4 of 5
http://www.ovarianresearch.com/content/7/1/11of a low-dose approach, including lower pregnancy rates
compared with conventional IVF, in addition to a lower
profit for IVF centers [6].
In underdeveloped or developing countries, infertility
treatment can involve more complex socioeconomic is-
sues, raising two main points: the problem of superpo-
pulation, about which it is argued that this should be the
focus of family planning programs; and, in view of the
high cost of an assisted reproduction treatment com-
pared to the low income of the population, that this in-
come should be directed towards higher priorities.
However, even in these countries, it is observed that the
consequences of infertility without a possibility of treat-
ment vary from a period of anguish to social isolation,
murder and even suicide [25].
As older health care demands are controlled, new
needs arise in our days, bringing about increasing
costs and the issue of universal access. In between
the public and the private sphere, the third sector
arises in the process of remodeling the institutional
managing ways as a combination of the several kinds
of arrangements between the State and the civil so-
ciety, so as to implement and co-manage public pol-
icies and to face the different manifestations of the
Brazilian social issues. Distant from a philanthropic
and charitable perspective, this “group” is organized
with the purpose of warranting the respect of the
rights resulting from the Constitution of 1988 and
the Organic Laws they entail.
Infertility treatment arises as an emerging need, as it is
estimated that in Brazil over 278,000 couples face dif-
ficulties in conceiving a child at some point of their
reproductive age. The development of new assisted
reproduction technologies and the search for success in
the treatment of human infertility have generated an in-
creasing demand for such treatments in the public sec-
tor, the third sector and the private services, even at a
significantly high cost.
Countless questionings have been brought up ever
since these techniques have been incorporated to the ar-
senal of medical procedures made available to the popu-
lation, and their use is more and more common in social
organizations that aim to ensure, by means of an inte-
grated set of actions, the constitutional rights, among
which health as a qualification of the civil right to life.
The technological advances bring about new question-
ings, such as the role of the State in the access of the
less favored population to modern treatments and all the
other necessities of a Third-World country. A health
care system that offers equitable access to basic health
care services is only viable when both patients and phy-
sicians realize that the interests of the individual patient
and of the social system must be balanced. This implies
that patients do not have a right to the most effectivetreatment [regardless of the cost] but only to the most
cost effective treatment [19].
Based on the cost of the medication used for con-
trolled ovarian stimulation, manufactured by several
pharmaceutical industries, the use of an initial dose of
100 IU of rFSH represents a saving of approximately
45% of the total cost of the treatment. This saving may
make it viable to offer low-income populations a possi-
bility to have children and make their dream of a family
come true.
Conclusion
In conclusion, the initial dose of 100 IU of rFSH was
considered adequate for controlled ovarian hyperstimu-
lation, aiming to reduce the costs of the assisted
reproduction treatment, considering 'patient-friendly’
assisted reproductive treatment.
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